

Clear all data

Go to 'Fe

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED.  
SECRETARY OF THE SENATE

05 FEB 15 AM 12:23

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
Organization		Biotechnology Industry Organization	
2. Address <input type="checkbox"/> Check if different than previously reported			
1225 Eye St., NW		Suite 400	
City	Washington	State	DC
		Zip Code	20005
Country USA			
3. Principal place of business (if different than line 2)			
City		State	
		Zip Code	
Country			
4a. Contact Name		b. Telephone number	c. E-mail
Prefix	Full Name		
Ms.	Heather S. Chaney	202-962-9200	hchaney@bio.org
5. Senate ID #			6245-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
Biotechnology Industry Organization			32050000

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30) ☐ OR Year End (July 1-December) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇒ Termination Date \_\_\_\_\_ 11. No Lobbying Activity ☐

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>2,660,000</u></p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions or</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of Internal Revenue Code</p>
--	--

Form Co

Printed Name and Title Michael Werner, Chief of Policy



Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code ACC - Accounting (one per page)

16. Specific lobbying issues

-HR 1372, S 979 Broad Based Stock Option Plan Transparency Act  
 -HR 3574, S 1890 Stock Option Accounting Reform Act  
 -HR 286, S 206 To Amend the Internal Revenue Code of 1986 to Clarify the Treatment of Incentive Stock Options and Employee Stock Purchase Plans  
 -HRes 725 Providing for the consideration of the bill HR 3574 to require the mandatory expensing of stock options

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House -IRS  
 -Senate  
 -Treasury  
 -Security & Exchange Commission  
 -White House

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Solon	Lawton		General Counsel
Morie	Ruffin		Vice President, Bus. Dev. & Emerging Companies
Libby	Solon		Director, Government Relations
Susie	Ahn		Manager, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

2/10/05

Printed Name and Title Michael Werner, Chief of Policy / '

LD-2DS (R)

Page 2

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**ADDENDUM for General Lobbying Issue Area ACC**

**16. Specific lobbying issues (continued from previous page)**

-HR 4520 American Jobs Creation Act of 2004

LD-2DS

MZemer

Add page to continue specific issues description for this is

2/10/05

Page 3

Client Name Biotechnology Industry Organization

15. General issue area code AGR - Agriculture (one per page)

- Proposed Policy re: Adventitious Presence
- Proposed Policy re: Animal Cloning
- HR 4651 To establish a Federal interagency taskforce to promote the benefits, safety, and potential uses of agricultural biotechnology outside the United States to improve human and animal
- HR 2546 Genetically Engineered Foods Act
- HR 4103 To extend and modify the trade benefits under the African Growth and Opportunity Act

- House
- Senate
- FDA
- USDA
- Dept. of State

- US Trade Representative
- EPA
- OSTP

Name		Covered Official Position (if applicable)
First Name	Last Name	Suffix
L. Val	Giddings	
Mike	Phillips	
Barbara	Glenn	
Sean	Darragh	

Filing #3ebdacef-917f-4d80-80d1-5c3c41aca2f2 - Page 7 of 50

2/10/05

Printed Name and Title Michael Werner, Chief of Policy

LD-2DS (REV. 4/03)

Page 4



Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**ADDENDUM for General Lobbying Issue Area** AGR

16. Specific lobbying issues (continued from previous page)

- HR 4766, S 2803 Agriculture Appropriations
- HR 4693 Seed Availability and Competition Act of 2004
- HR 4454 Ecoterrorism Prevention Act of 2004
- HR 1950 Foreign Relations Authorization Act, Fiscal Years 2004 & 2005
- HRes 252 Expressing the sense of the House of Representatives supporting the USA in its efforts within the WTO to end the European Union's protectionist and discriminatory trade policies of the past 5 years regarding agricultural biotechnology
- Animal biotech regulatory policy

*M. Weiner*

*2/10/05*

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

- Appropriations Bills (HR 4766 Agriculture; HR 4754 Commerce, Justice, State; HR 4613 & S 2559 Defense; HR 4614 Energy & Water; HR 4567 & 2537 Homeland Security; HR 4568 Interior; HR 4755 & S 2606 Legislative Branch)  
 -Supplemental Appropriations Bill  
 -HR 1561 PTO Fee Bill  
 -Omnibus Appropriations Bill

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House	-OSTP	-PTO
-Senate	-USDA	
-FDA	-EPA	
-HHS	- Dept. of Energy	
-OMB	- Dept. of Commerce	

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this issue

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Steve	Lawton		General Counsel
L. Val	Giddings		Vice President, Food and Agriculture
Libby	Solon		Director, Government Relations
Michael	Werner		Chief of Policy
Brent	Erickson		Vice President, Industrial & Environmental
Barbara	Glenn		Director, Intellectual Property
Lila	Feisee		Director, Intellectual Property

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

- HR 2391 & S 2192 CREATE ACT  
 -HR 1561 PTO Fee Bill  
 -HR 4754 Commerce, State, Justice Appropriations  
 -HR 5299 Patent Quality Assistance Act of 2004  
 -HR 5351 Office of Intellectual Property and Competition Policy Act of 2004  
 -HR 5117 Fortifying America's Intellectual Property Rights (FAIR) Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House  
 -Senate  
 -PTO  
 -NIH  
 -Dept. of Commerce, Office of Science Policy  
 -Dept. of State  
 -HHS  
 -US Trade Representative

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Michael	Werner		Chief of Policy
Lila	Felsee		Director, Intellectual Property
Libby	Solon		Director, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Werner, Chief of Policy

LD-2DS (REV. 4/03)

Page 7

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**ADDENDUM for General Lobbying Issue Area** CPT

**16. Specific lobbying issues (continued from previous page)**

- Human Cloning Patent Amendment

*M. H. H. H.*

*2/10/05*



Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code DEF - Defense (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

-S 15 Project BioShield  
 -S 666 Biological, Chemical, and Radiological Weapons Countermeasure Research Act of 2003  
 -HR 4613 & S 2559 Defense Appropriations  
 -HR 4454 Ecoterrorism Act of 2004  
 -Biobased Purchasing Policy  
 -Biothreat Countermeasures

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House  
 -Senate  
 -Dept. of Defense  
 -Dept of Homeland Security  
 -Office of the Vice President  
 -FDA  
 -HHS  
 -White House

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this issue

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Carl	Feldbaum		President
Brent	Erickson		Vice President, Industrial & Environmental
L. Val	Giddings		Vice President, Food and Agriculture
Steve	Lawton		General Counsel
Michael	Werner		Chief of Policy
Libby	Solon		Director, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Werner, Chief of Policy

LD-2DS (REV. 4/03)

Page 9

Client Name **Biotechnology Industry Organization**

15. General issue area code ENG - Energy/Nuclear (one per page)

Add page to continue specific issues description for this issue

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area*

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

2/10/05

Printed Name and Title Michael Werner, Chief of Policy

LD-2DS (R)

Page 10

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code FOO - Food Industry (Safety, Labeling, etc.) (one per page)

16. Specific lobbying issues

-HR 4766 Agriculture Appropriations  
 -HR 4665 Importation of Safe Food Act of 2004  
 -HR 4651 To establish a Federal interagency taskforce to promote the benefits, safety, and potential uses of agricultural biotechnology  
 -HR 2352 American Horse Slaughter Prevention Act of 2004  
 -S 2546 Genetically Engineered Foods Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House  
 -Senate  
 -EPA  
 -USDA  
 -FDA

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
L. Val	Giddings		Vice President, Food and Agriculture
Mike	Phillips		VP, Food and Ag, Science and Reg. Affairs

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

2/10/02

Printed Name and Title Michael Werner, Chief of Policy

/ /

LD-2DS (REV. 4/03)

Page 11

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**ADDENDUM for General Lobbying Issue Area** FOO

16. Specific lobbying issues (continued from previous page)

-Proposed policy re: Adventitious Presence  
-HRes 252 Expressing the sense of the House of Representatives supporting the USA in its efforts withing th  
WTO to end the European Union's protectionist and discriminatory trade practices of the past 5 years regard  
agricultural biotechnology

*M. Hemen*

*2/10/05*



Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HOM - Homeland Security (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue >

- S 15 Project BioShield  
-S 666 Biological, Chemical, and Radiological Weapons Countermeasures Research Act of 2003  
-HR 4454 Ecoterrorism Act of 2004  
-Biothreat Countermeasures

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House  
-Senate  
-Dept. of Defense  
-USDA  
-FDA  
-White House

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this issue

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Sara	Lawton		General Counsel
Morrie	Werner		Chief of Policy
Brent	Erickson		Vice President, Industrial & Environmental
Libby	Solon		Director, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

2/10/05

Printed Name and Title Michael Werner, Chief of Policy / /

LD-2DS (REV. 4/03)

Page 13

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MED - Medical/Disease Research/Clinical Labs (one per page)

16. Specific lobbying issues

-HR 4682 Stem Cell Research Enhancement Act of 2004  
 -HR 4812 Stem Cell Discovery Through Diversity Act  
 -HR 4531 Ronald Reagan Memorial Stem Cell Research Act of 2004  
 S 1053 Genetic Discrimination Act of 2003  
 -Labor HHS Appropriations  
 -Clinical Trial Information Disclosure

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House -Dept. of State  
 -Senate -CDC  
 -HHS -NIST  
 -NIH -White House  
 -FDA

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Michael	Werner		Chief of Policy
Libby	Solon		Director, Government Relations
Sara	Radcliffe		Managing Director, Science & Regulatory Affairs
Michael	Losow		Director, Outreach
Lila	Feisee		Director, Intellectual Property
Steve	Lawton		General Counsel

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

2/10/0

Printed Name and Title Michael Werner, Chief of Policy

LD-2DS (REV. 4/03)

Page 14

Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**ADDENDUM for General Lobbying Issue Area** MED

16. Specific lobbying issues (continued from previous page)

- Bayh-Dole March-in Rights
- NIH Conflict of Interest
- FDA Review Practices
- Cell, Gene and Tissue Therapy
- Pharmacogenomics
- PDUFA Implementation

*M. H. K. M.*

*2/12/05*

Client Name Biotechnology Industry Organization

15. General issue area code MMM - Medicare/Medicaid (one per page)

Add page to continue specific issues description for this issue

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for th*

[illegible]

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Werner, Chief of Policy / /

LD-2DS (REV. 4/03)

Page 16



Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues

-HR 4151 Brian Lykins Human Tissue Transplant Safety Act of 2004  
 -HR 4790 Drug Importation Promotion and Safety Act  
 -HR 4923 Safe IMPORT Act of 2004  
 -HR 5278 Community Pharmacy Preservation Act of 2004  
 -S 2652 Medicare Prescription Drug Savings and Choice Act of 2004  
 -HR 5155 Free Market Drug Act

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House  
 -Senate  
 -HHS  
 -FDA  
 -OMB  
 -White House

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Carl	Feldbaum		President
Michael	Werner		Chief of Policy
Steve	Lawton		General Counsel
Libby	Solon		Director, Intellectual Property
Sara	Radcliffe		Managing Director, Science & Regulatory Affairs
Susie	Ahn		Manager, Government Relations
Lila	Feisee		Director, Intellectual Property
Michael	Losow		Director, Outreach

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

2/10/05

Printed Name and Title Michael Werner, Chief of Policy / /

LD-2DS (REV. 4/03)

Page 17

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization**ADDENDUM for General Lobbying Issue Area** PHA

## 16. Specific lobbying issues (continued from previous page)

- FDA issues including: Post Market Surveillance, clinical trials, drug reviews, drug manufacturing, and counterfeiting.
- Prescription Drug User Fee Act (Implementation)

LD-2DS

*M Werner*

Add page to continue specific issues description for this i

*2/10/05* Page 18

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code SCI - Science/Technology (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

-HR 4149, S 2384 A bill to amend the Small Business Act to permit business concerns that are owned by venture capital operating companies or pension plans to participate in the Small Business Innovation Research Program  
 -HR 4656 Nanomanufacturing Investment Act of 2004  
 -HR 4503 Energy Policy Act of 2004

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House  
 -Senate  
 -SBA  
 -White House

18. Name of each individual who acted as a lobbyist in this issue area

Add a page to continue adding lobbyists for this issue

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Carl	Feldbaum		President
Morrie	Ruffin		Vice President, Bus. Dev. & Emerging Companies
Morrie	Werner		Chief of Policy
Brent	Erickson		Vice President, Industrial & Environmental
Steve	Lawton		General Counsel
Lila	Feisee		Director, Intellectual Property
Libby	Solon		Director, Government Relations
Susie	Ahn		Manager, Government Relations

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

2/10/05

Printed Name and Title Michael Werner, Chief of Policy / /

LD-2DS (REV. 4/03)

Page 19

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code SMB - Small Business (one per page)

16. Specific lobbying issues

Add page to continue specific issues description for this issue

- HR 4149, S 2384 A bill to amend the Small Business Act to permit business concerns that are owned by venture capital operating companies or pension plans to participate in the Small Business Innovation Research Program  
 -S 2821 Small Business Reauthorization and Manufacturing Assistance Act of 2004  
 -HR 5108 Small Business Reauthorization and Manufacturing Assistance Act of 2004

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

-House  
 -Senate  
 -SBA  
 -White House

18. Name of each individual who acted as a lobbyist in this issue area Add a page to continue adding lobbyists for this issue

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Carl	Feldbaum		President
Michael	Werner		Chief of Policy
Morrie	Ruffin		Vice President, Bus. Dev. & Emerging Companies
Libby	Solon		Director, Government Relations
Susie	Ahn		Manager, Government Relations
Lila	Feisee		Director, Intellectual Property

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Printed Name and Title Michael Werner, Chief of Policy

LD-2DS (REV. 4/03)

Page 20



Client Name **Biotechnology Industry Organization**

15. General issue area code

(one per page)

- HR 2968, S 1773 Biotechnology Future Investment Expansion Act of 2003
- HR 1308 Tax Relief, Simplification and Equity Act of 2003
- HR 2931 Orphan Drug Tax Credit Act of 2003
- HR 3574, S 1890 Stock Option Accounting Reform Act
- HR 1372, S 979 Broad Based Stock Option Plan Transparency Act of 2003
- HRes 725 Providing for the consideration of the bill HR 3574 to require the mandatory expensing of stock

- House
- Senate
- Treasury
- SEC
- White House

[illegible]


19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization**ADDENDUM for General Lobbying Issue Area** TAX

## 16. Specific lobbying issues (continued from previous page)

options  
-HR 4520 American Jobs Creation Act of 2004  
-HR 2896 American Jobs Creation Act of 2003  
-S 3019 Tax Technical Corrections Act of 2004

A handwritten signature in black ink, appearing to read "M. Keene", written in a cursive style.A handwritten date "2/10/05" in black ink, written in a cursive style.

Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

16. Specific lobbying issues

- WTO Case on Moratorium in EU  
 - WTO case on traceability and labeling  
 - General WTO Issues  
 - Importation legislation  
 - Trade relate IP agreements  
 - Harmonization efforts

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

- House  
 - Senate  
 - Exec. Office of the Pres - White House  
 - Exec. Office of the the VP - White House  
 - Dept. of State  
 - EPA  
 - USDA  
 - FDA  
 - USPTO  
 - US Trade Representative

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue area*

Name			Covered Official Position (if applicable)
First Name	Last Name	Suffix	
Michael	Werner		Chief of Policy
Sean	Darragh		Executive Director, Food and Agriculture
Brent	Erickson		Vice President, Industrial & Environmental
L. Val	Giddings		Vice President, Food and Agriculture
Libby	Solon		Director, Government Relations
Lila	Felsee		Director, Intellectual Property

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None



Registrant Name Biotechnology Industry OrganizationClient Name Biotechnology Industry Organization**ADDENDUM for General Lobbying Issue Area** TRD

## 16. Specific lobbying issues (continued from previous page)

**TRIPS**

*M Heme*

*2/10/05* Page 24



Registrant Name Biotechnology Industry Organization Client Name Biotechnology Industry Organization

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address

City

State

Zip Code

Country

21. Client new principal place of business (if different than line 20)

City

State

Zip Code

Country

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

First Name

Last Name

Suffix

First Name

Last Name

Su

1

Carl

Feldbaum

3

Jennifer

Berzok

2

Steve

Lawton

4

**ISSUE UPDATE**

Find the code to select below.

24. General lobbying issues that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)
	Address	City
	C/S/Z	State Country
	Address	City
	C/S/Z	State

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

1

2

3

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Street Address	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ow per clie
	City	State/Province Country	City		
			State Country		

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, affiliated organization

1

3

5

2

4

6

Printed Name and Title Michael Werner, Chief of Policy

